The menopause and aging symptoms are treated with hormone replacement (HRT). The hormones your body stops producing after menopause are replaced by synthetic hormones like progesterone and estrogen. For people with hormone shortages, hormone replacement therapy can assist in regaining balance and enhancing the quality of life.
The market for hormone replacement therapy in 2021 was USD 24.97 billion, and by 2030 it will be worth USD 49.25 billion, expanding at a 7.83% CAGR during the forecast period.
The growing awareness of post-menopausal concerns among women is a major factor driving the global market. In addition, the development of sophisticated drug delivery technology is accelerating market expansion globally. A bright outlook for the market is also being created by the rising investment by market participants in research and development (R&D) efforts to develop innovative therapies to treat hormonal abnormalities.
Market Dynamics
Drivers
The market will expand due to the rising prevalence of chronic diseases like adult male hypogonadism. Additionally, key firms would raise their product approvals and extend their R&D activities to develop novel medicines to address hormonal imbalances. Two major factors accelerating the growth of the global market for hormone replacement therapy are the rising prevalence of menopausal diseases and women’s increased awareness of the issues related to post-menopause. The Hormone Replacement Therapy Market will grow significantly due to recent introductions of hormone replacement therapy.
Restraints
The growth of the global market will be constrained by the high cost of hormone replacement therapy and the danger of developing cancer from HRTs. Furthermore, the market will be constrained by the risks associated with hormone replacement treatment, which include breast cancer, heart disease, stroke, and blood clots.
Opportunity
Pharmaceutical companies provide new cutting-edge medications to the worldwide market as a result of rising unmet hormone replacement demand in developing nations and greater knowledge of the treatment of hormone irregularities. In addition, the prevalence of menopause and hormone deficiency issues in important nations has prompted manufacturers to release novel items, such as combination therapy products, to replace the regular use of long-acting parenteral drugs.
Market Segmentation
By Product
On the basis of product, the market is segmented into testosterone replacement therapy, thyroid replacement therapy, parathyroid hormone replacement therapy, and estrogen and progesterone replacement therapy.
In 2021, estrogen and progesterone replacement therapy had the biggest market share of nearly 53.15%. The largest market share was due to an increase in the number of women experiencing menopause. The American Congress of Obstetricians and Gynecologists estimates that 6,000 women in the United States go through menopause daily.
Due to rising incidence and more product penetration, the parathyroid hormone replacement market is anticipated to develop quickly throughout the forecast period. The National Organization for Rare Disease’s 2021 database estimates that 70,000 Americans have hypoparathyroidism.
By Route of Administration
On the basis of the route of administration, the market is segmented into parental, oral, transdermal, and others.
The oral segment rule the market in 2021 because it is so easily administered and has a high prescription rate. Tablets and pills are typically included in HRT medicines.
During the forecast period, the parenteral segment will have profitable expansion. It will expand due to improvements in parenteral drug delivery techniques, such as pen-based medication delivery, which will increase patient compliance and simplify administration.
By Disease Type
On the basis of disease type, the market is segmented into hypothyroidism, male hypogonadism, menopause, growth hormone deficiency, and hypoparathyroidism.
In 2021, the menopause segment led the entire market with a significant revenue share. The largest market share is due to the rising number of women suffering from menopause.
Due to an increase in new treatments and product introductions, the hypoparathyroidism segment will grow significantly throughout the projected period.
Regional Analysis
North America was the biggest regional market, with a share of 37.54% in 2021. The biggest market share in the area is due to several reasons, including significant product launches, manufacturer collaboration agreements, and benevolent reimbursement policies.
The Asia-Pacific region will expand at a rapid rate during the forecast period. The prevalence of vasomotor symptoms linked with menopause has been observed to range from 43% to 83% among women in East Asian countries, according to the Journal of the North American Menopause Society (May 2022). Thus, the region’s demand for hormone replacement therapy will increase as more women enter menopause.
Key Players
- Bayer Ag.
- Hoffmann-La Roche Ltd. (Genentech, Inc.)
- Pfizer Inc.
- Abbott Laboratories
- Merck Kgaa
- Eli Lily And Company
- Novartis International Ag
- Hisamitsu Pharmaceutical Co., Inc. (Noven Pharmaceuticals, Inc.)
- Mylan N.V. (Viatris Inc.)
- Novo Nordisk A/S
The market for hormone replacement therapy in 2021 was USD 24.97 billion, and by 2030 it will be worth USD 49.25 billion, expanding at a 7.83% CAGR during the forecast period. Increased awareness of post-menopausal concerns among women, increased drug development with novel delivery technologies, and hormonal imbalance diseases with the growing senior population are some factors that favorably affect the growth of the hormone replacement therapy (HRT) market.
A review drove by the Oxford-Imperial School of General Experts Exploration and Reconnaissance Center concentrated on 1.8 million clinical records of ladies from 465 general specialists and found 5,451 Coronavirus cases connected with HRT (estrogen treatment) saw a 78% decrease in contamination and death rate. The male populace will in general have a more serious disease and higher paces of hospitalization and mortality.
The rising contribution of vital participants in the improvement of novel treatments is bringing about the presentation of new items on the lookout. For example, in January 2022, Ascendis Pharma A/S got the European Commission’s market approval for its medication SKYTROFA for the treatment of kids and young people experiencing development chemical problems. This item is the first once-week-by-week treatment for the development of chemical lack in the pediatric populace.
Expanding mindfulness about chemical inadequacy and problems is supposed to drive market development. For example, Kid Development Establishment is a UK-based non-government association devoted to supporting individuals living with uncommon development chemical problems.
Related Reports:
Video Analytics Market Report – The global video analytics market will witness a robust CAGR of 23.1%, valued at $4.5 Billion in 2021, and expected to appreciate and reach $5.5 Billion in 2022 and $35.6 Billion by 2030, confirms Strategic Market Research.
